MarketPulse

idiopathic pulmonary fibrosis

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oorja Bio Raises $30M to Develop First-in-Class IPF Therapy ORJ-001

Oorja Bio launches with $30M Series A to develop ORJ-001, a first-in-class peptide therapy for idiopathic pulmonary fibrosis, with Phase 2 trials planned for 2026.
MRKGILDPhase 2 clinical trialSeries A funding
GlobeNewswire Inc.GlobeNewswire Inc.··Agomab Therapeutics Nv

Agomab Raises $208M in IPO, Extends Runway to 2029 Amid Pipeline Progress

Agomab Therapeutics raised $208M in February 2026 IPO and reported €116.5M cash, funding operations into H1 2029 while advancing two lead drug candidates.
AGMBIPOclinical-stage biopharmaceutical
BenzingaBenzinga··Vandana Singh

United Therapeutics Surges 16.5% on Positive Lung Disease Trial Results

United Therapeutics stock surges 16.5% after TETON-1 Phase 3 study shows Tyvaso meets primary endpoint in lung fibrosis treatment, with priority FDA review expected by summer 2026.
UTHRFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Agomab Secures U.S. Patent for IPF Treatment AGMB-447 Through 2041

Agomab Therapeutics gains patent protection for AGMB-447, an inhaled lung-targeted therapy for idiopathic pulmonary fibrosis, with Phase 1b results expected in 2026.
AGMBintellectual propertyPhase 1b study